Lenvatinib versus sorafenib in first | 合法藥品大搜索

由 M Kudo 著作 · 2018 · 被引用 1767 次 — Methods: This was an open-label, phase 3, multicentre, non-inferiority trial that recruited patients with unresectable hepatocellular carcinoma, ... Read More

由 ZT Al-Salama 著作 · 2019 · 被引用 28 次 — Lenvatinib (Lenvima®) is an oral small molecule inhibitor of multiple receptor tyrosine kinases, and is approved for the first-line treatment of patients ... Read More

由 JJ Kim 著作 · 被引用 13 次 — Recently, lenvatinib became the first agent in more than 10 years to receive approval as first-line therapy for unresectable HCC, along with the ... Read More

由 M Kudo 著作 · 2018 · 被引用 1767 次 — Lenvatinib was non-inferior to sorafenib in overall survival in untreated advanced hepatocellular carcinoma. The safety and tolerability ... Read More

由 N Personeni 著作 · 2019 · 被引用 32 次 — Lenvatinib for first-line treatment of HCC ... Lenvatinib is an oral multikinase inhibitor that inhibits vascular endothelial growth factor (VEGF) ... Read More

由 A Dipasquale 著作 · 2021 · 被引用 1 次 — Lenvatinib versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma-new therapeutic scenario. Read More

由 J Cheon 著作 · 2020 · 被引用 11 次 — Current international guidelines recommend lenvatinib as the first-line therapy for patients with advanced HCC [12-15]. Real-world evidence is important in HCC ... Read More

2021年1月17日 — Lenvatinib Effective as First Line Therapy for Patients with Hepatocellular Carcinoma ... Lenvatinib monotherapy was an effective first-line ... Read More

在治療RCC的Study 205、治療HCC的REFLECT試驗與治療DTC的. SELECT試驗中，接受Lenvima®或Lenvima®併用everolimus治療之病. 人，分別有2%、2%及5%發生動脈血管栓塞，在所有 ... Read More

由 T Hatanaka 著作 · 2021 — Hepatocellular carcinoma (HCC) is the most frequent type of primary liver cancer, which accounts for approximately 80% of all cases [1]. Read More